Science News About Treatments
- NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases
The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program, aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases.
- Researchers Use Exosome-Based Strategy to Block HIV in Mice
In this NIMH-funded study, researchers used exosomes to deliver novel protein into the cells of mice infected with HIV. The protein attached to HIV’s genetic material and prevented it from replicating, resulting in reduced levels of HIV in the bone marrow, spleen, and brain.
- NIMH’s Carlos Zarate Jr., M.D., Elected to National Academy of Medicine
Carlos Zarate Jr., M.D., chief of the Experimental Therapeutics and Pathophysiology Branch within the NIMH Intramural Research Program, has been elected to the National Academy of Medicine.
- Neural Signature Identifies People Likely to Respond to Antidepressant Medication
NIH-funded research uses machine learning algorithm to predict individual response to a commonly-prescribed antidepressant.
- Side Effects Mild, Brief with Single Antidepressant Dose of Intravenous Ketamine
A single, low-dose ketamine infusion was relatively free of side effects for patients with treatment-resistant depression.
- NIH Announces Funding Awards for National Early Psychosis Learning Community
NIMH awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis.
- Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression
FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.